Contribute to the Site - CN
Cancer Network's content includes news, articles from the journal ONCOLOGY, blogs, Image IQs, case studies, videos, and podcasts.
Please send any inquiries or contributions to our managing editor, Ian Ingram: ian.ingram@ubm.com
Blogging
Interested in blogging? We are looking for oncologists interested in contributing regular commentary about life in practice and the ever-changing world of oncology and hematology. Our bloggers generally contribute monthly.
Case Studies
Have a compelling case to share? Submit cases to be posted to our Case Studies section, and we’ll send you $50. Cases must include images with descriptions and a short write-up that includes history, findings, diagnosis, and a discussion.
Image IQ
Have a case that would work great in quiz format? Submit your case to be posted to our Image IQ section, and we’ll send you $75. Image IQs must include an image, clinical history, a question with multiple answer choices, and a discussion of the correct answer.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
